{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T22:39:21Z","timestamp":1785278361176,"version":"3.55.0"},"reference-count":142,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T00:00:00Z","timestamp":1531958400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Gastroenterol Hepatol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1038\/s41575-018-0045-2","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T09:15:13Z","timestamp":1531991713000},"page":"753-764","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Novel perspectives in the management of decompensated cirrhosis"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1308-5440","authenticated-orcid":false,"given":"Mauro","family":"Bernardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1439-056X","authenticated-orcid":false,"given":"Paolo","family":"Caraceni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,19]]},"reference":[{"key":"45_CR1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","volume":"44","author":"G D\u2019Amico","year":"2006","unstructured":"D\u2019Amico, G., Garcia-Tsao, G. & Pagliaro, L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J. Hepatol. 44, 217\u2013231 (2006).","journal-title":"J. Hepatol."},{"issue":"Suppl. 1","key":"45_CR2","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0168-8278(12)60003-8","volume":"56","author":"P Gin\u00e9s","year":"2012","unstructured":"Gin\u00e9s, P., Fern\u00e1ndez, J., Durand, F. & Saliba, F. Management of critically-ill cirrhotic patients. J. Hepatol. 56 (Suppl. 1), S13\u2013S24 (2012).","journal-title":"J. Hepatol."},{"key":"45_CR3","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1053\/j.gastro.2013.02.042","volume":"144","author":"R Moreau","year":"2013","unstructured":"Moreau, R. et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 144, 1426\u20131437 (2013).","journal-title":"Gastroenterology"},{"key":"45_CR4","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jhep.2014.08.010","volume":"61","author":"A Albillos","year":"2014","unstructured":"Albillos, A., Lario, M. & Alvarez-Mon, M. Cirrhosis-associated immune dysfunction: distinct features and clinical relevance. J. Hepatol. 61, 1385\u20131396 (2014).","journal-title":"J. Hepatol."},{"key":"45_CR5","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.1840080532","volume":"8","author":"RW Schrier","year":"1988","unstructured":"Schrier, R. W. et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8, 1151\u20131157 (1988).","journal-title":"Hepatology"},{"key":"45_CR6","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jhep.2012.03.007","volume":"57","author":"JC Garc\u00eda-Pag\u00e1n","year":"2012","unstructured":"Garc\u00eda-Pag\u00e1n, J. C., Gracia-Sancho, J. & Bosch, J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J. Hepatol. 57, 458\u2013461 (2012).","journal-title":"J. Hepatol."},{"key":"45_CR7","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nrgastro.2013.210","volume":"11","author":"S Wiese","year":"2014","unstructured":"Wiese, S., Hove, J. D., Bendtsen, F. & M\u00f8ller, S. Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nat. Rev. Gastroenterol. Hepatol. 11, 177\u2013186 (2014).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"45_CR8","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.jhep.2007.02.001","volume":"46","author":"V Arroyo","year":"2007","unstructured":"Arroyo, V., Terra, C. & Gin\u00e9s, P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J. Hepatol. 46, 935\u2013946 (2007).","journal-title":"J. Hepatol."},{"issue":"2 Suppl. 1","key":"45_CR9","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1002\/hep.20993","volume":"43","author":"Y Iwakiri","year":"2006","unstructured":"Iwakiri, Y. & Groszmannm, R. J. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 43 (2 Suppl. 1), S121\u2013S131 (2006).","journal-title":"Hepatology"},{"key":"45_CR10","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jhep.2015.07.004","volume":"63","author":"M Bernardi","year":"2015","unstructured":"Bernardi, M., Moreau, R., Angeli, P., Schnabl, B. & Arroyo, V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J. Hepatol. 63, 1272\u20131284 (2015).","journal-title":"J. Hepatol."},{"key":"45_CR11","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jhep.2013.07.044","volume":"60","author":"R Wiest","year":"2014","unstructured":"Wiest, R., Lawson, M. & Geuking, M. Pathological bacterial translocation in liver cirrhosis. J. Hepatol. 60, 197\u2013209 (2014).","journal-title":"J. Hepatol."},{"key":"45_CR12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/path.2274","volume":"214","author":"S Sriskandan","year":"2008","unstructured":"Sriskandan, S. & Altmann, D. M. The immunology of sepsis. J. Pathol. 214, 211\u2013223 (2008).","journal-title":"J. Pathol."},{"key":"45_CR13","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","volume":"11","author":"T Kawai","year":"2010","unstructured":"Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11, 373\u2013384 (2010).","journal-title":"Nat. Immunol."},{"key":"45_CR14","doi-asserted-by":"crossref","first-page":"16045","DOI":"10.1038\/nrdp.2016.45","volume":"2","author":"RS Hotchkiss","year":"2016","unstructured":"Hotchkiss, R. S. et al. Sepsis and septic shock. Nat. Rev. Dis. Primers. 2, 16045 (2016).","journal-title":"Nat. Rev. Dis. Primers."},{"key":"45_CR15","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/hep.28740","volume":"64","author":"J Cl\u00e0ria","year":"2016","unstructured":"Cl\u00e0ria, J. et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology 64, 1249\u20131264 (2016).","journal-title":"Hepatology"},{"key":"45_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.024","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J. Hepatol. \n                    https:\/\/doi.org\/10.1016\/j.jhep.2018.03.024\n                    \n                   (2018).","journal-title":"J. Hepatol."},{"key":"45_CR17","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nrgastro.2013.51","volume":"10","author":"J O\u2019Brien","year":"2013","unstructured":"O\u2019Brien, J., Triantos, C. & Burroughs, A. K. Management of varices in patients with cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 10, 402\u2013412 (2013).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"45_CR18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.dld.2016.10.011","volume":"49","author":"S Fagiuoli","year":"2017","unstructured":"Fagiuoli, S. et al. Consensus conference on TIPS management: techniques, indications, contraindications. Dig. Liver Dis. 49, 121\u2013137 (2017).","journal-title":"Dig. Liver Dis."},{"key":"45_CR19","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/nrgastro.2010.116","volume":"7","author":"R Prakash","year":"2010","unstructured":"Prakash, R. & Mullen, K. D. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat. Rev. Gastroenterol. Hepatol. 7, 515\u2013525 (2010).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"45_CR20","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1002\/hep.28330","volume":"63","author":"J Fern\u00e1ndez","year":"2016","unstructured":"Fern\u00e1ndez, J., Tandon, P., Mensa, J. & Garcia-Tsao, G. Antibiotic prophylaxis in cirrhosis: good and bad. Hepatology 63, 2019\u20132031 (2016).","journal-title":"Hepatology"},{"key":"45_CR21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.addr.2017.05.016","volume":"121","author":"K B\u00f6ttcher","year":"2017","unstructured":"B\u00f6ttcher, K. & Pinzani, M. Pathophysiology of liver fibrosis and the methodological barriers to the development of anti-fibrogenic agents. Adv. Drug. Deliv. Rev. 121, 3\u20138 (2017).","journal-title":"Adv. Drug. Deliv. Rev."},{"key":"45_CR22","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S0140-6736(12)61425-1","volume":"381","author":"P Marcellin","year":"2013","unstructured":"Marcellin, P. et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381, 468\u2013475 (2013).","journal-title":"Lancet"},{"key":"45_CR23","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/j.gastro.2016.03.036","volume":"151","author":"V Marco Di","year":"2016","unstructured":"Di Marco, V. et al. Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension. Gastroenterology 151, 130\u2013139 (2016).","journal-title":"Gastroenterology"},{"key":"45_CR24","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","volume":"152","author":"P Nahon","year":"2017","unstructured":"Nahon, P. et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 152, 142\u2013156 (2017).","journal-title":"Gastroenterology"},{"key":"45_CR25","doi-asserted-by":"crossref","first-page":"bcr2013201618","DOI":"10.1136\/bcr-2013-201618","volume":"2014","author":"H Takahashi","year":"2014","unstructured":"Takahashi, H., Shigefuku, R., Maeyama, S. & Suzuki, M. Cirrhosis improvement to alcoholic liver fibrosis after passive abstinence. BMJ Case Rep. 2014, bcr2013201618 (2014).","journal-title":"BMJ Case Rep."},{"key":"45_CR26","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hep.28280","volume":"63","author":"AS Lok","year":"2016","unstructured":"Lok, A. S. et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology 63, 284\u2013306 (2016).","journal-title":"Hepatology"},{"key":"45_CR27","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","volume":"373","author":"MP Curry","year":"2015","unstructured":"Curry, M. P. et al. Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis. N. Engl. J. Med. 373, 2618\u20132628 (2015).","journal-title":"N. Engl. J. Med."},{"key":"45_CR28","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","volume":"64","author":"GR Foster","year":"2016","unstructured":"Foster, G. R. et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J. Hepatol. 64, 1224\u20131231 (2016).","journal-title":"J. Hepatol."},{"key":"45_CR29","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","volume":"65","author":"MC Cheung","year":"2016","unstructured":"Cheung, M. C. et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J. Hepatol. 65, 741\u2013747 (2016).","journal-title":"J. Hepatol."},{"key":"45_CR30","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/liv.13588","volume":"38","author":"S Martini","year":"2017","unstructured":"Martini, S. et al. The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: a national real-life experience. Liver Int. 38, 733\u2013741 (2017).","journal-title":"Liver Int."},{"key":"45_CR31","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0168-8278(01)00228-8","volume":"36","author":"BJ Veldt","year":"2002","unstructured":"Veldt, B. J. et al. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J. Hepatol. 36, 93\u201398 (2002).","journal-title":"J. Hepatol."},{"key":"45_CR32","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/hep.29097","volume":"65","author":"CF Carrillo","year":"2017","unstructured":"Carrillo, C. F. et al. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: analysis of data from the Hepa-C Registry. Hepatology 65, 1810\u20131822 (2017).","journal-title":"Hepatology"},{"key":"45_CR33","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.jhep.2017.08.008","volume":"67","author":"JM Pascasio","year":"2017","unstructured":"Pascasio, J. M. et al. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. J. Hepatol. 67, 1168\u20131176 (2017).","journal-title":"J. Hepatol."},{"key":"45_CR34","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jhep.2009.11.007","volume":"52","author":"JH Shim","year":"2010","unstructured":"Shim, J. H. et al. Efficacy of entecavir in treatment-na\u00efve patients with hepatitis B virus-related decompensated cirrhosis. J. Hepatol. 52, 176\u2013182 (2010).","journal-title":"J. Hepatol."},{"key":"45_CR35","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1097\/MCG.0b013e3182284e13","volume":"45","author":"MA Alvarez","year":"2011","unstructured":"Alvarez, M. A. et al. Long-term clinical course of decompensated alcoholic cirrhosis. A prospective study of 165 patients. J. Clin. Gastroenterol. 45, 906\u2013911 (2011).","journal-title":"J. Clin. Gastroenterol."},{"key":"45_CR36","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1097\/MEG.0b013e32834a75dc","volume":"23","author":"J Trebicka","year":"2011","unstructured":"Trebicka, J. et al. Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt. Eur. J. Gastroenterol. Hepatol. 23, 1218\u20131225 (2011).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"45_CR37","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jhep.2016.10.025","volume":"66","author":"J Trebicka","year":"2017","unstructured":"Trebicka, J. Emergency TIPS in a Child-Pugh B patient: when does the window of opportunity open and close? J. Hepatol. 66, 442\u2013450 (2017).","journal-title":"J. Hepatol."},{"key":"45_CR38","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jhep.2014.09.032","volume":"62","author":"ML Berres","year":"2015","unstructured":"Berres, M. L. et al. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt insertion. J. Hepatol. 62, 332\u2013339 (2015).","journal-title":"J. Hepatol."},{"key":"45_CR39","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/jgh.13303","volume":"31","author":"SA Halabi","year":"2016","unstructured":"Halabi, S. A. et al. Early TIPS versus endoscopic therapy for secondary prophylaxis after management of acute esophageal variceal bleeding in cirrhotic patients: a meta-analysis of randomized controlled trials. J. Gastroenterol. Hepatol. 31, 1519\u20131526 (2016).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"45_CR40","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1053\/j.gastro.2007.06.020","volume":"133","author":"F Salerno","year":"2007","unstructured":"Salerno, F., Camm\u00e0, C., Enea, M., R\u00f6ssle, M. & Wong, F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 133, 825\u2013834 (2007).","journal-title":"Gastroenterology"},{"key":"45_CR41","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/MCG.0b013e3182a115e9","volume":"48","author":"RP Chen","year":"2014","unstructured":"Chen, R. P. et al. Prophylactic use of transjugular intrahepatic portosystemic shunt aids in the treatment of refractory ascites: metaregression and trial sequential meta-analysis. J. Clin. Gastroenterol. 48, 290\u2013299 (2014).","journal-title":"J. Clin. Gastroenterol."},{"key":"45_CR42","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1053\/j.gastro.2016.09.016","volume":"152","author":"C Bureau","year":"2017","unstructured":"Bureau, C. et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology 152, 157\u2013163 (2017).","journal-title":"Gastroenterology"},{"key":"45_CR43","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","volume":"63","author":"R Franchis De","year":"2015","unstructured":"De Franchis, R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J. Hepatol. 63, 743\u2013752 (2015).","journal-title":"J. Hepatol."},{"key":"45_CR44","first-page":"132","volume":"80","author":"K Ohnishi","year":"1985","unstructured":"Ohnishi, K. et al. Effects of propranolol on portal hemodynamics in patients with chronic liver disease. Am. J. Gastroenterol. 80, 132\u2013135 (1985).","journal-title":"Am. J. Gastroenterol."},{"key":"45_CR45","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1002\/hep.23689","volume":"51","author":"J Bosch","year":"2010","unstructured":"Bosch, J. Carvedilol for portal hypertension in patients with cirrhosis. Hepatology 51, 2214\u20132218 (2010).","journal-title":"Hepatology"},{"key":"45_CR46","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1136\/gut.2006.091322","volume":"55","author":"RH Straub","year":"2006","unstructured":"Straub, R. H., Wiest, R., Strauch, U. G., H\u00e4rle, P. & Sch\u00f6lmerich, J. The role of the sympathetic nervous system in intestinal inflammation. Gut 55, 1640\u20131649 (2006).","journal-title":"Gut"},{"key":"45_CR47","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s12325-013-0044-1","volume":"30","author":"BS Madsen","year":"2013","unstructured":"Madsen, B. S., Havelund, T. & Krag, A. Targeting the gut-liver axis in cirrhosis: antibiotics and non-selective \u03b2-blockers. Adv. Ther. 30, 659\u2013670 (2013).","journal-title":"Adv. Ther."},{"key":"45_CR48","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hep.510310109","volume":"31","author":"M Perez-Paramo","year":"2000","unstructured":"Perez-Paramo, M. et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology 31, 43\u201348 (2000).","journal-title":"Hepatology"},{"key":"45_CR49","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1136\/gut.2009.185413","volume":"59","author":"M Worlicek","year":"2010","unstructured":"Worlicek, M. et al. Splanchnic sympathectomy prevents translocation and spreading of E coli but not S aureus in liver cirrhosis. Gut 59, 1127\u20131134 (2010).","journal-title":"Gut"},{"key":"45_CR50","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jhep.2012.12.011","volume":"58","author":"T Reiberger","year":"2013","unstructured":"Reiberger, T. et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J. Hepatol. 58, 911\u2013921 (2013).","journal-title":"J. Hepatol."},{"key":"45_CR51","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1111\/j.1478-3231.2009.02038.x","volume":"29","author":"M Senzolo","year":"2009","unstructured":"Senzolo, M. et al. Beta-blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int. 29, 1189\u20131193 (2009).","journal-title":"Liver Int."},{"key":"45_CR52","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1111\/liv.12593","volume":"35","author":"M Merli","year":"2015","unstructured":"Merli, M. et al. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int. 35, 362\u2013369 (2015).","journal-title":"Liver Int."},{"key":"45_CR53","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.23775","volume":"52","author":"T Serst\u00e9","year":"2010","unstructured":"Serst\u00e9, T. et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 52, 1017\u20131022 (2010).","journal-title":"Hepatology"},{"key":"45_CR54","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1053\/j.gastro.2014.03.005","volume":"146","author":"M Mandorfer","year":"2014","unstructured":"Mandorfer, M. et al. Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 146, 1680\u20131690 (2014).","journal-title":"Gastroenterology"},{"key":"45_CR55","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.jhep.2015.10.018","volume":"64","author":"RP Mookerjee","year":"2016","unstructured":"Mookerjee, R. P. et al. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. J. Hepatol. 64, 574\u2013582 (2016).","journal-title":"J. Hepatol."},{"key":"45_CR56","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jhep.2011.11.024","volume":"56","author":"N Shah","year":"2012","unstructured":"Shah, N. et al. Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression. J. Hepatol. 56, 1047\u20131053 (2012).","journal-title":"J. Hepatol."},{"issue":"Suppl. 1","key":"45_CR57","first-page":"83A","volume":"66","author":"S Kainth","year":"2017","unstructured":"Kainth, S. et al. Efficacy and safety of Carvedilol in patients of acute-on-chronic liver failure with small or no esophageal varices. A placebo control open label randomised trial. Hepatology 66 (Suppl. 1), 83A (2017).","journal-title":"Hepatology"},{"key":"45_CR58","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.jhep.2014.01.024","volume":"60","author":"R Jalan","year":"2014","unstructured":"Jalan, R. et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J. Hepatol. 60, 1310\u20131324 (2014).","journal-title":"J. Hepatol."},{"key":"45_CR59","first-page":"1719","volume":"21","author":"BA Runyon","year":"1995","unstructured":"Runyon, B. A. et al. Effect of selective bowel decontamination with norfloxacin on spontaneous bacterial peritonitis, translocation, and survival in an animal model of cirrhosis. Hepatology 21, 1719\u20131724 (1995).","journal-title":"Hepatology"},{"key":"45_CR60","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1002\/hep.510230419","volume":"23","author":"JM Llovet","year":"1996","unstructured":"Llovet, J. M. et al. Selective intestinal decontamination with norfloxacin reduces bacterial translocation in ascitic cirrhotic rats exposed to hemorrhagic shock. Hepatology 23, 781\u2013787 (1996).","journal-title":"Hepatology"},{"key":"45_CR61","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1053\/jhep.2003.50038","volume":"37","author":"A Albillos","year":"2003","unstructured":"Albillos, A. et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 37, 208\u2013217 (2003).","journal-title":"Hepatology"},{"key":"45_CR62","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/0016-5085(92)91514-5","volume":"103","author":"G Soriano","year":"1992","unstructured":"Soriano, G. et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 103, 1267\u20131272 (1992).","journal-title":"Gastroenterology"},{"issue":"Suppl. 2","key":"45_CR63","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000051423","volume":"59","author":"B Bernard","year":"1998","unstructured":"Bernard, B. et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with ascites: a meta-analysis. Digestion 59 (Suppl. 2), 54\u201357 (1998).","journal-title":"Digestion"},{"key":"45_CR64","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.cgh.2008.12.018","volume":"7","author":"R Loomba","year":"2009","unstructured":"Loomba, R., Wesley, R., Bain, A., Csako, G. & Pucino, F. Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis. Clin. Gastroenterol. Hepatol. 7, 487\u2013493 (2009).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"45_CR65","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1053\/j.gastro.2007.06.065","volume":"133","author":"J Fern\u00e1ndez","year":"2007","unstructured":"Fern\u00e1ndez, J. et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 133, 818\u2013824 (2007).","journal-title":"Gastroenterology"},{"issue":"Suppl. 1","key":"45_CR66","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0168-8278(17)30264-7","volume":"66","author":"R Moreau","year":"2017","unstructured":"Moreau, R. et al. A randomized trial of 6-month norfloxacin therapy in patients with Child-Pugh class C cirrhosis. J. Hepatol. 66 (Suppl. 1), S1 (2017).","journal-title":"J. Hepatol."},{"key":"45_CR67","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1086\/520273","volume":"26","author":"B Campillo","year":"1998","unstructured":"Campillo, B., Dupeyron, C., Richardet, J. P., Mangeney, N. & Leluan, G. Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. Clin. Infect. Dis. 26, 1066\u20131070 (1998).","journal-title":"Clin. Infect. Dis."},{"key":"45_CR68","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/hep.25532","volume":"55","author":"J Fern\u00e1ndez","year":"2012","unstructured":"Fern\u00e1ndez, J. et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 55, 1551\u20131561 (2012).","journal-title":"Hepatology"},{"key":"45_CR69","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1086\/499950","volume":"42","author":"JA Adachi","year":"2006","unstructured":"Adachi, J. A. & Dupont, H. L. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin. Infect. Dis. 42, 541\u2013547 (2006).","journal-title":"Clin. Infect. Dis."},{"key":"45_CR70","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.anaerobe.2017.10.002","volume":"48","author":"E Reigadas","year":"2017","unstructured":"Reigadas, E. et al. Rifaximin-resistant Clostridium difficile strains isolated from symptomatic patients. Anaerobe 48, 269\u2013272 (2017).","journal-title":"Anaerobe"},{"key":"45_CR71","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ijantimicag.2009.11.013","volume":"35","author":"ZD Jiang","year":"2010","unstructured":"Jiang, Z. D., Ke, S. & Dupont, H. L. Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei. Int. J. Antimicrob. Agents 35, 278\u2013281 (2010).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"45_CR72","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1128\/AAC.00691-09","volume":"54","author":"EL Brown","year":"2010","unstructured":"Brown, E. L., Xue, Q., Jiang, Z. D., Xu, Y. & Dupont, H. L. Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. Antimicrob. Agents Chemother. 54, 388\u2013396 (2010).","journal-title":"Antimicrob. Agents Chemother."},{"key":"45_CR73","volume":"8","author":"JS Bajaj","year":"2013","unstructured":"Bajaj, J. S. et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLOS ONE 8, e60042 (2013).","journal-title":"PLOS ONE"},{"key":"45_CR74","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1159\/000068362","volume":"66","author":"S Fiorucci","year":"2002","unstructured":"Fiorucci, S. et al. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion 66, 246\u2013256 (2002).","journal-title":"Digestion"},{"key":"45_CR75","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.cgh.2012.02.025","volume":"10","author":"GN Kalambokis","year":"2012","unstructured":"Kalambokis, G. N. et al. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. Clin. Gastroenterol. Hepatol. 10, 815\u2013818 (2012).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"45_CR76","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/hep.28898","volume":"65","author":"N Kimer","year":"2017","unstructured":"Kimer, N. et al. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial. Hepatology 65, 592\u2013603 (2017).","journal-title":"Hepatology"},{"key":"45_CR77","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nature13568","volume":"513","author":"N Qin","year":"2014","unstructured":"Qin, N. et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 513, 59\u201364 (2014).","journal-title":"Nature"},{"key":"45_CR78","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa0907893","volume":"362","author":"NM Bass","year":"2010","unstructured":"Bass, N. M. et al. Rifaximin treatment in hepatic encephalopathy. N. Engl. J. Med. 362, 1071\u20131081 (2010).","journal-title":"N. Engl. J. Med."},{"key":"45_CR79","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/MCG.0b013e3182506dbb","volume":"46","author":"MA Hanouneh","year":"2012","unstructured":"Hanouneh, M. A. et al. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J. Clin. Gastroenterol. 46, 709\u2013715 (2012).","journal-title":"J. Clin. Gastroenterol."},{"key":"45_CR80","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/jgh.12070","volume":"28","author":"J Vlachogiannakos","year":"2013","unstructured":"Vlachogiannakos, J. et al. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J. Gastroenterol. Hepatol. 28, 450\u2013455 (2013).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"45_CR81","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1007\/s10620-016-4313-0","volume":"61","author":"T Dong","year":"2016","unstructured":"Dong, T., Aronsohn, A., Gautham Reddy, K. & Te, H. S. Rifaximin decreases the incidence and severity of acute kidney injury and hepatorenal syndrome in cirrhosis. Dig. Dis. Sci. 61, 3621\u20133626 (2016).","journal-title":"Dig. Dis. Sci."},{"key":"45_CR82","volume":"9","author":"P Lutz","year":"2014","unstructured":"Lutz, P. et al. Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites. PLOS ONE 9, e93909 (2014).","journal-title":"PLOS ONE"},{"key":"45_CR83","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/MEG.0000000000000743","volume":"28","author":"AS Hanafy","year":"2016","unstructured":"Hanafy, A. S. & Hassaneen, A. M. Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival. Eur. J. Gastroenterol. Hepatol. 28, 1455\u20131461 (2016).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"Suppl. 1","key":"45_CR84","first-page":"1027A","volume":"64","author":"JS Bajaj","year":"2016","unstructured":"Bajaj, J. S. et al. Oral rifaximin soluble solid dispersion immediate-release 40 mg prevents development of cirrhosis-related complications: a phase 2, randomized, multicenter, double-blind, placebo-controlled trial. Hepatology 64 (Suppl. 1), 1027A (2016).","journal-title":"Hepatology"},{"key":"45_CR85","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/MEG.0000000000000940","volume":"29","author":"F Kamal","year":"2017","unstructured":"Kamal, F. et al. Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis. Eur. J. Gastroenterol. Hepatol. 29, 1109\u20131117 (2017).","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"45_CR86","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/liv.13551","volume":"38","author":"I G\u00f3mez-Hurtado","year":"2018","unstructured":"G\u00f3mez-Hurtado, I. et al. Norfloxacin is more effective than rifaximin in avoiding bacterial translocation in an animal model of cirrhosis. Liver Int. 38, 295\u2013302 (2018).","journal-title":"Liver Int."},{"key":"45_CR87","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jgh.13852","volume":"33","author":"N Kimer","year":"2018","unstructured":"Kimer, N. et al. Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: a randomized trial. J. Gastroenterol. Hepatol. 33, 307\u2013314 (2018).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"45_CR88","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","volume":"143","author":"E Villa","year":"2012","unstructured":"Villa, E. et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 143, 1253\u20131260 (2012).","journal-title":"Gastroenterology"},{"key":"45_CR89","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jhep.2015.12.003","volume":"64","author":"F Cerini","year":"2016","unstructured":"Cerini, F. et al. Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats. J. Hepatol. 64, 834\u2013842 (2016).","journal-title":"J. Hepatol."},{"key":"45_CR90","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/liv.13510","volume":"38","author":"JI Fortea","year":"2018","unstructured":"Fortea, J. I. et al. Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis. Liver Int. 38, 102\u2013112 (2018).","journal-title":"Liver Int."},{"key":"45_CR91","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.12.007","volume":"104","author":"BL Copple","year":"2016","unstructured":"Copple, B. L. & Li, T. Pharmacology of bile acid receptors: evolution of bile acids from simple detergents to complex signaling molecules. Pharmacol. Res. 104, 9\u201321 (2016).","journal-title":"Pharmacol. Res."},{"key":"45_CR92","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00535-015-1041-8","volume":"50","author":"E Distrutti","year":"2015","unstructured":"Distrutti, E. et al. Bile acid activated receptors are targets for regulation of integrity of gastrointestinal mucosa. J. Gastroenterol. 50, 707\u2013719 (2015).","journal-title":"J. Gastroenterol."},{"key":"45_CR93","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajpath.2014.10.009","volume":"185","author":"L Verbeke","year":"2015","unstructured":"Verbeke, L. et al. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. Am. J. Pathol. 185, 409\u2013419 (2015).","journal-title":"Am. J. Pathol."},{"key":"45_CR94","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jhep.2015.12.010","volume":"64","author":"M Ubeda","year":"2016","unstructured":"Ubeda, M. et al. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. J. Hepatol. 64, 1049\u20131057 (2016).","journal-title":"J. Hepatol."},{"key":"45_CR95","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.dld.2014.07.008","volume":"46","author":"P Lutz","year":"2014","unstructured":"Lutz, P. et al. A farnesoid X receptor polymorphism predisposes to spontaneous bacterial peritonitis. Dig. Liver Dis. 46, 1047\u20131050 (2014).","journal-title":"Dig. Liver Dis."},{"key":"45_CR96","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep.26939","volume":"59","author":"L Verbeke","year":"2014","unstructured":"Verbeke, L. et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 59, 2286\u20132298 (2014).","journal-title":"Hepatology"},{"key":"45_CR97","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens, F. et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N. Engl. J. Med. 375, 631\u2013643 (2016).","journal-title":"N. Engl. J. Med."},{"key":"45_CR98","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jhep.2013.12.019","volume":"60","author":"JS Bajaj","year":"2014","unstructured":"Bajaj, J. S. et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J. Hepatol. 60, 940\u2013947 (2014).","journal-title":"J. Hepatol."},{"key":"45_CR99","first-page":"249","volume":"5","author":"H Fukui","year":"2017","unstructured":"Fukui, H. Gut microbiome-based therapeutics in liver cirrhosis: basic consideration for the next step. J. Clin. Transl Hepatol. 5, 249\u2013260 (2017).","journal-title":"J. Clin. Transl Hepatol."},{"key":"45_CR100","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jhep.2017.05.007","volume":"67","author":"R Wiest","year":"2017","unstructured":"Wiest, R. Albillos, A., Trauner, M., Bajaj, J. S. & Jalan, R. Targeting the gut-liver axis in liver disease. J. Hepatol. 67, 1084\u20131103 (2017).","journal-title":"J. Hepatol."},{"key":"45_CR101","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/liv.13005","volume":"36","author":"S Saab","year":"2016","unstructured":"Saab, S. et al. Probiotics are helpful in hepatic encephalopathy: a meta-analysis of randomized trials. Liver Int. 36, 986\u2013993 (2016).","journal-title":"Liver Int."},{"key":"45_CR102","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/MCG.0000000000000789","volume":"51","author":"D Viramontes H\u00f6rner","year":"2017","unstructured":"Viramontes H\u00f6rner, D., Avery, A. & Stow, R. The effects of probiotics and symbiotics on risk factors for hepatic encephalopathy: a systematic review. J. Clin. Gastroenterol. 51, 312\u2013323 (2017).","journal-title":"J. Clin. Gastroenterol."},{"key":"45_CR103","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/apt.14397","volume":"47","author":"CA Woodhouse","year":"2017","unstructured":"Woodhouse, C. A., Patel, V. C., Singanayagam, A. & Shawcross, D. L. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment. Pharmacol. Ther. 47, 192\u2013202 (2017).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"45_CR104","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1016\/j.jacc.2014.01.054","volume":"63","author":"D Tousoulis","year":"2014","unstructured":"Tousoulis, D. et al. Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. J. Am. Coll. Cardiol. 63, 2491\u20132502 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"45_CR105","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/hep.21673","volume":"46","author":"J Trebicka","year":"2007","unstructured":"Trebicka, J. et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA\/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 46, 242\u2013253 (2007).","journal-title":"Hepatology"},{"key":"45_CR106","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1053\/j.gastro.2009.01.043","volume":"136","author":"JG Abraldes","year":"2009","unstructured":"Abraldes, J. G. et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 136, 1651\u20131658 (2009).","journal-title":"Gastroenterology"},{"key":"45_CR107","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.dld.2015.07.156","volume":"47","author":"P Pollo-Flores","year":"2015","unstructured":"Pollo-Flores, P. et al. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial. Dig. Liver. Dis. 47, 957\u2013963 (2015).","journal-title":"Dig. Liver. Dis."},{"key":"45_CR108","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1053\/j.gastro.2003.12.007","volume":"126","author":"C Zafra","year":"2004","unstructured":"Zafra, C. et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 126, 749\u2013755 (2004).","journal-title":"Gastroenterology"},{"key":"45_CR109","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1053\/j.gastro.2016.01.004","volume":"150","author":"JG Abraldes","year":"2016","unstructured":"Abraldes, J. G. et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology 150, 1160\u20131170 (2016).","journal-title":"Gastroenterology"},{"key":"45_CR110","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jhep.2015.07.006","volume":"63","author":"YH Yang","year":"2015","unstructured":"Yang, Y. H. et al. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection. J. Hepatol. 63, 1111\u20131117 (2015).","journal-title":"J. Hepatol."},{"key":"45_CR111","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/ajg.2016.179","volume":"111","author":"YW Huang","year":"2016","unstructured":"Huang, Y. W. et al. Statins Reduce the risk of cirrhosis and its decompensation in chronic hepatitis B patients: a nationwide cohort study. Am. J. Gastroenterol. 111, 976\u2013985 (2016).","journal-title":"Am. J. Gastroenterol."},{"key":"45_CR112","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/hep.28506","volume":"64","author":"TG Simon","year":"2016","unstructured":"Simon, T. G., Bonilla, H., Yan, P., Chung, R. T. & Butt, A. A. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: results from ERCHIVES. Hepatology 64, 47\u201357 (2016).","journal-title":"Hepatology"},{"key":"45_CR113","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1053\/j.gastro.2015.10.007","volume":"150","author":"A Mohanty","year":"2016","unstructured":"Mohanty, A., Tate, J. P. & Garcia-Tsao, G. Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis. Gastroenterology 150, 430\u2013440 (2016).","journal-title":"Gastroenterology"},{"key":"45_CR114","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/apt.14243","volume":"46","author":"UC Bang","year":"2017","unstructured":"Bang, U. C., Benfield, T. & Bendtsen, F. Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case-cohort study. Aliment. Pharmacol. Ther. 46, 673\u2013680 (2017).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"45_CR115","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1002\/hep.29172","volume":"66","author":"FM Chang","year":"2017","unstructured":"Chang, F. M. et al. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population-based study. Hepatology 66, 896\u2013907 (2017).","journal-title":"Hepatology"},{"key":"45_CR116","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1053\/j.gastro.2016.06.055","volume":"151","author":"RA Weersink","year":"2016","unstructured":"Weersink, R. A., Drenth, J. P. & Borgsteede, S. D. Altered pharmacokinetics of statins explain increased risk of rhabdomyolysis in advanced cirrhosis. Gastroenterology 151, 1036 (2016).","journal-title":"Gastroenterology"},{"key":"45_CR117","volume":"7","author":"S Rodr\u00edguez","year":"2017","unstructured":"Rodr\u00edguez, S. et al. A nitric oxide-donating statin decreases portal pressure with a better toxicity profile than conventional statins in cirrhotic rats. Sci. Rep. 7, 40461 (2017).","journal-title":"Sci. Rep."},{"key":"45_CR118","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM199908053410603","volume":"341","author":"P Sort","year":"1999","unstructured":"Sort, P. et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N. Engl. J. Med. 341, 403\u2013409 (1999).","journal-title":"N. Engl. J. Med."},{"key":"45_CR119","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/hep.24786","volume":"55","author":"M Bernardi","year":"2012","unstructured":"Bernardi, M., Caraceni, P., Navickis, R. J. & Wilkes, M. M. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology 55, 1172\u20131181 (2012).","journal-title":"Hepatology"},{"key":"45_CR120","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1053\/jhep.2002.35819","volume":"36","author":"R Ortega","year":"2002","unstructured":"Ortega, R. et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 36, 941\u2013948 (2002).","journal-title":"Hepatology"},{"key":"45_CR121","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.26338","volume":"58","author":"R Garcia-Martinez","year":"2013","unstructured":"Garcia-Martinez, R. et al. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology 58, 1836\u20131846 (2013).","journal-title":"Hepatology"},{"key":"45_CR122","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jceh.2014.08.007","volume":"4","author":"M Bernardi","year":"2014","unstructured":"Bernardi, M., Ricci, C. S. & Zaccherini, G. Role of human albumin in the management of complications of liver cirrhosis. J. Clin. Exp. Hepatol. 4, 302\u2013311 (2014).","journal-title":"J. Clin. Exp. Hepatol."},{"key":"45_CR123","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.jhep.2013.06.013","volume":"59","author":"K Oettl","year":"2013","unstructured":"Oettl, K. et al. Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival. J. Hepatol. 59, 978\u2013983 (2013).","journal-title":"J. Hepatol."},{"key":"45_CR124","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/hep.27322","volume":"60","author":"M Domenicali","year":"2014","unstructured":"Domenicali, M. et al. Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology 60, 1851\u20131860 (2014).","journal-title":"Hepatology"},{"key":"45_CR125","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1111\/liv.12860","volume":"35","author":"FA Giannone","year":"2015","unstructured":"Giannone, F. A. et al. Ischaemia-modified albumin: a marker of bacterial infection in hospitalized patients with cirrhosis. Liver Int. 35, 2425\u20132432 (2015).","journal-title":"Liver Int."},{"key":"45_CR126","doi-asserted-by":"crossref","DOI":"10.1038\/srep35987","volume":"6","author":"M Baldassarre","year":"2016","unstructured":"Baldassarre, M. et al. Albumin homodimers in patients with cirrhosis: clinical and prognostic relevance of a novel identified structural alteration of the molecule. Sci. Rep. 6, 35987 (2016).","journal-title":"Sci. Rep."},{"key":"45_CR127","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/hep.26021","volume":"57","author":"A Bortoluzzi","year":"2013","unstructured":"Bortoluzzi, A. et al. Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms. Hepatology 57, 266\u2013276 (2013).","journal-title":"Hepatology"},{"key":"45_CR128","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/hep.20829","volume":"42","author":"J Fern\u00e1ndez","year":"2005","unstructured":"Fern\u00e1ndez, J. et al. A randomized unblinded pilot study comparing albumin vs. hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 42, 627\u2013634 (2005).","journal-title":"Hepatology"},{"key":"45_CR129","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nm.3516","volume":"20","author":"AJ O\u2019Brien","year":"2014","unstructured":"O\u2019Brien, A. J. et al. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. Nat. Med. 20, 518\u2013523 (2014).","journal-title":"Nat. Med."},{"key":"45_CR130","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0168-8278(99)80194-9","volume":"30","author":"P Gentilini","year":"1999","unstructured":"Gentilini, P. et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J. Hepatol. 30, 639\u2013645 (1999).","journal-title":"J. Hepatol."},{"key":"45_CR131","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.3748\/wjg.v12.i9.1403","volume":"12","author":"RG Romanelli","year":"2006","unstructured":"Romanelli, R. G. et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World. J. Gastroenterol. 12, 1403\u20131407 (2006).","journal-title":"World. J. Gastroenterol."},{"key":"45_CR132","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1016\/S0140-6736(18)30840-7","volume":"391","author":"P Caraceni","year":"2018","unstructured":"Caraceni, P. et al. Long-term albumin administration in decompensated cirrhosis: an open label randomized trial. Lancet 391, 2417\u20132429 (2018).","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"45_CR133","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0168-8278(17)30285-4","volume":"66","author":"E Sol\u00e0","year":"2017","unstructured":"Sol\u00e0, E. et al. Midodrine and albumin for prevention of complications of cirrhosis in patients in the waiting list for liver transplantation. A randomized, multicenter, double-blind, placebo-controlled trial. J. Hepatol. 66 (Suppl. 1), S11 (2017).","journal-title":"J. Hepatol."},{"key":"45_CR134","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1053\/j.gastro.2015.02.054","volume":"148","author":"CK Kedarisetty","year":"2015","unstructured":"Kedarisetty, C. K. et al. Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis. Gastroenterology 148, 1362\u20131370 (2015).","journal-title":"Gastroenterology"},{"key":"45_CR135","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29763","author":"N Verma","year":"2017","unstructured":"Verma, N. et al. Outcomes after multiple courses of granulocyte-colony stimulating factor and growth hormone in decompensated cirrhosis: randomized trial. Hepatology. \n                    https:\/\/doi.org\/10.1002\/hep.29763\n                    \n                   (2017).","journal-title":"Hepatology"},{"key":"45_CR136","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1002\/hep.28693","volume":"64","author":"KT Suk","year":"2016","unstructured":"Suk, K. T. et al. Transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: phase 2 trial. Hepatology 64, 2185\u20132197 (2016).","journal-title":"Hepatology"},{"key":"45_CR137","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S2468-1253(17)30326-6","volume":"3","author":"PN Newsome","year":"2018","unstructured":"Newsome, P. N. et al. Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial. Lancet Gastroenterol. Hepatol. 3, 25\u201336 (2018).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"45_CR138","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03202498\n                    \n                   (2018)."},{"key":"45_CR139","unstructured":"US National Library of Medicine. ClinicalTrials.gov \n                    https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03150459\n                    \n                   (2018)."},{"key":"45_CR140","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/jcsm.12095","volume":"8","author":"M Kalafately","year":"2017","unstructured":"Kalafately, M. et al. Malnutrition and sarcopenia predict post-liver transplantation outcomes independently of the Model for End-stage Liver Disease score. J. Cachexia Sarcopenia Muscle 8, 113\u2013121 (2017).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"45_CR141","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.cgh.2011.08.028","volume":"10","author":"A Montano-Loza","year":"2012","unstructured":"Montano-Loza, A. et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin. Gastroenterol. Hepatol. 10, 166\u2013173 (2012).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"45_CR142","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.29219","volume":"66","author":"JC Lai","year":"2017","unstructured":"Lai, J. C. et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology 66, 564\u2013574 (2017).","journal-title":"Hepatology"}],"container-title":["Nature Reviews Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41575-018-0045-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41575-018-0045-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41575-018-0045-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:50:34Z","timestamp":1684619434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41575-018-0045-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,19]]},"references-count":142,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["45"],"URL":"https:\/\/doi.org\/10.1038\/s41575-018-0045-2","relation":{},"ISSN":["1759-5045","1759-5053"],"issn-type":[{"value":"1759-5045","type":"print"},{"value":"1759-5053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,19]]},"assertion":[{"value":"19 July 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.B. has been a scientific consultant for Baxalta, CSL Behring and Grifols and speaker for AbbVie Italia, Baxalta, CSL Behring, Gilead Science, Grifols and Octapharma. P.C. has been a speaker for Baxalta, Grifols, Kedrion and Octapharma. He also participates in advisory boards for Grifols and has been a scientific consultant for Kedrion. He is also the recipient of a research grant from Octapharma.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}